Gain Therapeutics CEO to Present at H.C. Wainwright Conference — Gain Therapeutics, Inc.

Event summary

Gain Therapeutics CEO Gene Mack to participate in one-on-one meetings at H.C. Wainwright 28th Annual Global Investment Conference (September 14-16, 2026).
On-demand company presentation available September 11, 2026, with 90-day replay.
Lead drug candidate rexaceract in Phase 1b trial for Parkinson’s disease.
Company has multiple preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.

The big picture

Gain Therapeutics' participation in the H.C. Wainwright conference underscores its focus on engaging with investors amid critical clinical milestones. The company's lead candidate, rexaceract, targets high-need indications like Parkinson’s disease, positioning it in a competitive but growing segment of neurodegenerative disease treatments. Success in these areas could attract strategic partnerships or licensing deals, crucial for a clinical-stage biotech.

What we're watching

Clinical Progress: How the Phase 1b trial results for rexaceract will impact Gain Therapeutics' valuation and investor confidence.
Pipeline Development: Whether Gain can advance its preclinical assets into clinical trials to diversify its pipeline.
Market Positioning: The pace at which Gain can establish itself as a leader in allosteric small molecule therapies.